Newsroom

Bionaut industry news and features

Newsweek Interview with Michael Shpigelmacher, CEO & Founder Bionaut Labs.

In five years, Bionaut Labs will hopefully be recognized as a pioneer and a major platform company in the field of remote-controlled micro-robots, potentially as a public entity or a substantial private organization. Our vision includes treating a wide array of conditions across various payload types, expanding beyond neuro-oncology to areas like neuro-regeneration, pain management, and epilepsy, while also exploring territories outside the CNS.
Read more

Exclusive: Bionaut Labs raises an extension round in preparation for micro-robot clinical trials.

Bionaut’s raises an extension round, which involved the Mayo Clinic and Gates Ventures, along with existing investors Khosla Ventures, Upfront Ventures, and OurCrowd.
Learn more

Bionaut selected as a Norrsken Impact/100 company!

Our passion and commitment to creating positive change have propelled us to earn a spot as a Norrsken Impact/100 awardee!
Learn more

Team behind Apple’s Face ID develops tiny robots to deliver drugs into brain

Bionaut Labs has raised $43.2mn in second financing round to fund first clinical trials
Read More

Bionaut Labs uses $43M to prepare for clinical trials

The L.A. startup develops precision micro-robotic technology to deliver therapies to the center of the brain
Learn More

California start-up hopes to send micro-robots into human brains

California start-up hopes to send micro-robots into human brains. Agence France-Presse
Watch Video

Press Releases

November 28, 2022
Bionaut Labs Closes $43M in Series B Led by Khosla Ventures to Advance First-in-Class Micro-Robotic Technology and Remove Barriers to Treat Rare and Debilitating Diseases
Bionaut Labs, the company that uses microscale robots to revolutionize the treatment of central nervous system (CNS) diseases and disorders, today announced $43.2M in a Series B round of financing led by Khosla Ventures, bringing the company’s total financing raised to date to $63.2 million.

October 27, 2022
Dandy-Walker Alliance to Collaborate with Bionaut Labs
The Dandy-Walker Alliance is collaborating with Bionaut Labs to educate our constituency about an investigational new treatment for obstructive hydrocephalus associated with Dandy-Walker Syndrome.

December 15, 2021
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies
Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors

September 23, 2021
FDA Grants Humanitarian Use Device Designation to Bionaut Labs for Treatment of Dandy Walker Syndrome
The U.S. Food and Drug Administration (FDA) has granted the Company humanitarian use device (HUD) designation for BNL-201 for the local treatment of Dandy Walker Syndrome, a rare pediatric neurological disorder.

June 24, 2021
FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients
The U.S. Food and Drug Administration (FDA) has granted Bionaut Labs orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in pediatric and adult patients.

March 3, 2021
Bionaut Labs Debuts From Stealth Mode to Accelerate Development of New Precision Treatment Modality for Brain Disorders
Announced its launch backed by $20 million financing led by Khosla Ventures.